NTUS - NTUS STOCK NEWS

Natus Medical (NASDAQ:NTUS) reported Q1 2022 revenue of $119.8 million, a 4.2% increase from Q1 2021. Operating cash flow reached $8.9 million. GAAP EPS was $0.06, down from $0.07 in the previous year, while non-GAAP EPS rose to $0.22 from $0.16. The company faced over $3.4 million in extraordinary supply chain costs. Natus also announced plans to be acquired by ArchiMed for approximately $1.2 billion, with shareholders set to receive $33.50 per share. The transaction is expected to finalize in Q3 2022, leading to the suspension of financial guidance.

Natus Medical, Incorporated (NASDAQ: NTUS) has announced its acquisition by ArchiMed for approximately $1.2 billion. Shareholders will receive $33.50 per share, reflecting a 29% premium over the April 14 closing price. The merger has been unanimously approved by Natus’s Board of Directors and is expected to close in Q3 2022, pending shareholder and regulatory approvals. Natus reported a 4.3% revenue increase to $119.8 million in Q1 2022 but incurred $3.4 million in extraordinary supply chain costs. Financial guidance will no longer be updated due to the transaction.

Natus Medical Incorporated (NASDAQ: NTUS) announced it will release its 2022 Q1 financial results on May 5, 2022, after market close. A conference call will follow on May 6 at 8:00 a.m. ET to discuss the results. Interested listeners can join via phone or the Internet. Natus, a leader in medical solutions for central nervous and sensory system disorders, operates in over 100 countries, providing advanced diagnostic and treatment solutions aimed at improving patient outcomes.

Natus Medical (NTUS) reported Q4 2021 revenue of $128.7 million, an 8.4% increase year-over-year. Full-year revenue reached $473.4 million, up 13.9% from 2020. While GAAP EPS was $0.05 for Q4, non-GAAP EPS improved to $0.47, reflecting a 200% increase. The company plans to realign its portfolio focusing on the brain and nervous systems, estimating 2022 revenue between $491 million and $499 million, with non-GAAP EPS guidance of $1.36 to $1.49, including $16 million in extraordinary costs.

Natus Medical Incorporated (NASDAQ:NTUS) announced preliminary revenue figures for Q4 2021, expecting between $127.5 million and $128.5 million, and full-year revenue of $472.3 million to $473.3 million. Despite facing supply chain challenges that increased costs, the company achieved high single-digit revenue growth. CEO Thomas J. Sullivan noted the firm's ability to meet customer demand but indicated that supply chain costs limited profitability. Full financial results will be disclosed on February 24, 2021.

On January 7, 2022, Natus Medical Incorporated (NASDAQ: NTUS) announced that CEO Thomas J. Sullivan and CFO Drew Davies will present at the 24th Annual Needham Virtual Growth Conference on January 14, 2022, from 2:00 PM to 2:40 PM ET. Additionally, they will conduct one-on-one meetings with institutional investors. Interested investors can contact a Needham representative to schedule a meeting. A live webcast of the presentation will be available through the company’s website, with a recording accessible for 30 days thereafter.

Natus Medical Incorporated (NASDAQ: NTUS) will release its 2021 fourth quarter financial results on February 24 after market close. A conference call to discuss these results will take place on February 25 at 8:00 a.m. ET. Interested parties can join via telephone or listen online. Details for the call include domestic dialing at 1-844-634-1441 and an international line at 1-508-637-5658. A replay will be accessible for 48 hours post-call.

Natus Medical Incorporated (NASDAQ:NTUS) announced the appointment of Thomas J. Sullivan as President & Chief Executive Officer, effective December 27, 2021. Sullivan, a seasoned executive with over 20 years in the medical device industry, aims to enhance Natus' market leadership and innovation. The Board of Directors, after engaging a strategic consulting firm, recognized his capabilities during a rigorous succession planning process. Despite leadership changes, the company maintains its 4th quarter guidance outlook, highlighting its commitment to long-term growth and shareholder value.

Natus Medical reported Q3 2021 revenue of $113.9 million, an 11% increase from Q3 2020. GAAP EPS was $0.16, with a net income of $5.6 million, recovering from a net loss of $9.3 million last year. Non-GAAP EPS rose to $0.28, up from $0.09 in 2020. For the nine months ended September 30, 2021, revenue totaled $344.8 million, a 16.1% increase, with a non-GAAP EPS of $0.73. The company anticipates Q4 2021 revenue between $124 million and $128 million, amid ongoing supply chain challenges.